Ultomiris (Ravulizumab)

Ravulizumab is a medicine used to treat rare conditions such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis, and NMOSD. It is given as an infusion into a vein every few weeks. It works by blocking part of the immune system called complement that can attack blood cells, nerves, and muscles.

Brand names:Ultomiris
Medication

What people taking Ultomiris (Ravulizumab) report

Every report comes from a Lived member, sent anonymously.

Have you tried Ultomiris (Ravulizumab) for Paroxysmal Hemoglobinuria?

NameHow it went

About Ultomiris (Ravulizumab)

What It's For

Ravulizumab, sold as Ultomiris, is an infused antibody medicine for four rare diseases in which part of the immune system, called complement, damages the body's own cells. It is approved for paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder in which complement destroys red blood cells, and for atypical hemolytic uremic syndrome (aHUS), in which complement injures small blood vessels and often the kidneys. For both, it can be used in adults and in children from 1 month of age. It is not a treatment for the more common form of HUS caused by Shiga toxin-producing E. coli food poisoning. In adults, it is also approved for generalized myasthenia gravis, a disorder that causes muscle weakness, in people whose blood tests positive for acetylcholine receptor (AChR) antibodies, and for neuromyelitis optica spectrum disorder (NMOSD), which causes attacks of inflammation in the optic nerves and spinal cord, in people who test positive for aquaporin-4 (AQP4) antibodies. These antibody tests matter because they show the disease is driven by complement, the process this medicine blocks. Ultomiris is a longer-acting relative of eculizumab (Soliris), an older medicine with the same target that is given every 2 weeks rather than every 8.

How It Works

Complement is a group of blood proteins that normally helps destroy bacteria. When it is switched on, a protein called C5 is split into pieces, one of which starts building a structure that punches holes in cell membranes. In PNH, red blood cells lack a natural shield against this attack and burst. In aHUS, uncontrolled complement damages blood vessel linings. In myasthenia gravis and NMOSD, the body's own antibodies trigger complement at the nerve-muscle junction or in the optic nerve and spinal cord. Ravulizumab is a laboratory-made antibody that latches onto C5 and stops it from being split, so this final destructive step cannot happen. It does not remove the disease-causing antibodies or correct the underlying defect, which is why treatment is usually ongoing. It is engineered to stay in the blood for a long time (a half-life of roughly 50 to 65 days), which allows infusions every 8 weeks for most people. The same blockade that protects cells also weakens one of the body's main defenses against certain bacteria, which is the source of its most serious risk.

Dosage & Administration

Ultomiris is given as an intravenous (IV) infusion in a clinic or infusion center, or sometimes at home by a nurse. Treatment starts with a larger loading dose, followed by the first maintenance dose 2 weeks later. After that, adults and children weighing at least 20 kg (about 44 pounds) receive infusions every 8 weeks, while smaller children with PNH or aHUS receive them every 4 weeks. The dose is set by body weight. An infusion usually takes under 2 hours, and staff watch for reactions for about an hour afterward. People switching from Soliris generally start Ultomiris on the day their next Soliris dose would have been due. Before the first dose, meningococcal vaccines (covering the A, C, W, Y and B groups) should be completed or updated at least 2 weeks in advance. If treatment cannot wait, antibiotics are prescribed to cover the gap until the vaccines take effect, and booster shots continue during treatment. Children also need up-to-date vaccines against pneumococcus and Haemophilus influenzae type b (Hib). Keeping to the schedule matters because protection depends on steady drug levels. If an infusion is missed, contact the care team right away.

Side Effects

The most common side effects are cold-like upper respiratory infections and headache. People treated for aHUS also commonly have diarrhea, nausea, vomiting, high blood pressure and fever, although some of these reflect the illness itself. Back pain, joint pain and urinary tract infections were common in the NMOSD study. Infusion reactions, such as back or belly pain, chills, muscle spasms, a change in blood pressure or a bad taste, affected roughly 1 to 7 percent of people in studies and usually settle when the infusion is slowed or paused. Severe allergic reactions are rare. The most important danger is meningococcal infection, a bacterial infection of the blood or the lining of the brain that can become fatal within hours. Get emergency medical care right away, and show your Patient Safety Card, for fever (with or without a rash or a fast heartbeat), headache with fever, nausea or vomiting, a stiff neck or back, confusion, eyes that are sensitive to light, or muscle aches with flu-like symptoms. Report any other new sign of infection to the care team promptly.

Interactions & Warnings

Ultomiris carries the FDA's most serious (boxed) warning: it greatly increases the risk of life-threatening meningococcal infection, and people have died. Vaccination lowers but does not remove this risk. For that reason it is available only through a restricted safety program (the Ultomiris and Soliris REMS), in which the prescriber explains the risk and gives you a Patient Safety Card. Carry the card at all times during treatment and for 8 months after the last dose, because the risk lasts that long. Treatment should not be started in someone who has an untreated serious meningococcal infection. Blocking complement also raises the risk of infections from related bacteria, including gonorrhea that spreads through the body and, especially in children, pneumococcus and Hib. People at risk of sexually transmitted infections should discuss prevention and regular testing. Plasma exchange and intravenous immunoglobulin (IVIg, an infusion of pooled antibodies), both used in myasthenia gravis and NMOSD flares, wash ravulizumab out of the blood and need an extra dose. FcRn blockers such as efgartigimod (Vyvgart), another myasthenia gravis medicine that lowers antibody levels, may make it less effective. There are no human data on safety in pregnancy, but untreated PNH and aHUS carry serious risks for both parent and baby, so anyone pregnant or planning pregnancy should plan with the care team. Breastfeeding is not recommended during treatment and for 8 months after the last dose.

What to Expect

In PNH, ravulizumab usually reduces red cell destruction within weeks, which can ease fatigue and lower the need for transfusions. Progress is tracked with blood tests such as LDH (lactate dehydrogenase), an enzyme released when red cells break apart, where a falling level suggests less destruction. In a large trial it worked as well as Soliris while needing far fewer infusions. Some people with PNH continue to have anemia because red cells are still cleared in the liver and spleen, a problem C5 blockers do not address and other add-on medicines may. In aHUS, the aim is to stop the blood vessel damage and recover platelet counts and, where possible, kidney function. In the main adult study, about half of people met the full definition of response within 26 weeks; many others improved partly. Treatment lasts at least 6 months, and how long beyond that is decided individually. In myasthenia gravis, improvement in daily activities such as chewing, talking and climbing stairs can appear within weeks, but it is usually partial and varies widely; most people keep their other treatments. In NMOSD, the goal is preventing attacks, and none of the people in its main study had a confirmed relapse during treatment. Stopping can let the disease return. After stopping, people with PNH are monitored for at least 16 weeks for renewed red cell destruction, and people with aHUS for at least 12 months for signs such as confusion, seizures, chest pain, shortness of breath or rising blood pressure.

Questions to Ask Your Doctor

  1. 1.Why is Ultomiris a better fit for me than Soliris or another treatment for my condition?
  2. 2.Which vaccines do I need before starting, when are boosters due, and will I take antibiotics?
  3. 3.How will we measure whether it is working, and how soon should I expect changes?
  4. 4.If I need plasma exchange, IVIg or another new medicine, how will my Ultomiris doses be adjusted?
  5. 5.What would stopping involve, and how would we watch for my condition coming back?

Last reviewed • Oct 2026

Educational content, not medical advice.